Clozapine is an atypical antipsychotic indicated for treatment-resistant schizophrenia and for reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder. It is considered the gold standard for treatment-resistant schizophrenia but requires intensive monitoring due to the risk of agranulocytosis and other serious adverse effects.
Clinical Overview
Primary Clinical Applications
Clozapine is indicated for treatment-resistant schizophrenia (failure to respond to at least two other antipsychotics) and for reducing suicide risk in schizophrenia patients. It is the most effective antipsychotic for treatment-resistant cases and has unique anti-suicidal properties not seen with other antipsychotics.
Mechanism and Clinical Benefits
Clozapine has a complex receptor profile with activity at dopamine, serotonin, histamine, and cholinergic receptors. Its unique mechanism provides superior efficacy for treatment-resistant psychosis while having minimal risk of extrapyramidal side effects and tardive dyskinesia.
Monitoring Requirements
Clozapine requires mandatory blood monitoring due to risk of agranulocytosis. Patients must be enrolled in a REMS program with regular CBC monitoring (weekly for first 6 months, then biweekly, then monthly). This intensive monitoring is essential but allows access to the most effective treatment for resistant cases.
Key Clinical Points
Superior efficacy in treatment-resistant schizophrenia
Clozapine remains the only agent with established superiority in schizophrenia that has failed to respond to two adequate trials of other antipsychotics. It is widely regarded as underused relative to the evidence base.
Absolute neutrophil count monitoring
Severe neutropenia carries a boxed warning and requires structured ANC monitoring under a risk evaluation and mitigation programme, weekly at initiation and at reduced frequency thereafter.
Myocarditis risk in early treatment
Myocarditis and cardiomyopathy occur most often within the first eight weeks. Unexplained tachycardia, fever, chest pain, or dyspnoea during this window warrants urgent cardiac evaluation including troponin and CRP.
Seizure risk is dose-related
Seizure threshold falls with increasing dose and with rapid titration. Doses above approximately 600 mg daily carry appreciable risk, and anticonvulsant prophylaxis is sometimes required at higher doses.
Smoking cessation raises plasma levels
Tobacco smoke induces CYP1A2. Stopping smoking, including during inpatient admission, can raise clozapine concentrations substantially and precipitate toxicity. Dose review is required whenever smoking status changes.
Prescribing Information
Dosing & Administration
Treatment-Resistant Schizophrenia – Adults:
- Initial: 12.5 mg once or twice daily
- Titration: Increase by 25-50 mg daily to reach 300-450 mg daily by end of 2 weeks
- Target range: 300-600 mg daily in divided doses
- Maximum: 900 mg daily
Suicide Risk Reduction:
- Same dosing schedule as treatment-resistant schizophrenia
- Maintenance: 300-600 mg daily
Administration:
- Divide daily dose (doses >200 mg may be given once daily at bedtime)
- Take with or without food
- ODT formulation dissolves in mouth without water
Indications
- Treatment-resistant schizophrenia
- Reducing suicide risk in patients with schizophrenia or schizoaffective disorder
Contraindications
- Hypersensitivity to clozapine
- History of clozapine-induced agranulocytosis or severe granulocytopenia
- Uncontrolled epilepsy
- Paralytic ileus
- CNS depression or comatose states
Warnings & Precautions
- Boxed Warning: Agranulocytosis, seizures, myocarditis, increased mortality in elderly with dementia
- REMS program: Mandatory enrollment and blood monitoring required
- Agranulocytosis: Weekly CBC for 6 months, then biweekly for 6 months, then monthly
- Seizures: Dose-related risk, especially >600 mg daily
- Myocarditis: Monitor for signs during first month
- Metabolic effects: Significant weight gain, diabetes, dyslipidemia risk
Drug Interactions
- CYP1A2 inhibitors: Increase clozapine levels (fluvoxamine, ciprofloxacin)
- CYP1A2 inducers: Decrease clozapine levels (smoking, carbamazepine)
- CNS depressants: Enhanced sedation and respiratory depression
- Anticholinergics: Increased anticholinergic effects
Adverse Reactions
Common (≥5%):
- Sedation, dizziness, tachycardia, constipation
- Nausea, weight gain, fever, hypersalivation
Serious:
- Agranulocytosis (0.7-2%), seizures (1-5%), myocarditis
- Severe constipation, paralytic ileus
Special Populations
- REMS Program: All patients must be enrolled with regular monitoring
- Smoking cessation: May require dose increase due to CYP1A2 induction
- Elderly: Increased mortality risk in dementia-related psychosis
- Pregnancy: Category B – use only if benefits outweigh risks
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
